Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.

Bevacizumab, an anti vascular endothelial growth factor antibody is licensed in several tumours and widely used in colorectal cancer. However, bevacizumab has several adverse effects which may appear unexpectedly and differ according to the tumour.